Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02AUB
|
|||
| Former ID |
DCL000069
|
|||
| Drug Name |
Bimosiamose
|
|||
| Synonyms |
TBC 1269; TBC-1269
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Atopic dermatitis [ICD-11: EA80; ICD-10: L20] | Phase 2a | [1] | |
| Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J44, J44.9] | Phase 2a | [1] | ||
| Psoriatic disorder [ICD-11: EA90] | Phase 2a | [1] | ||
| Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Phase 2 | [1] | ||
| Company |
Encysive Pharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C46H54O16
|
|||
| Canonical SMILES |
C1=CC(=CC(=C1)C2=C(C=CC(=C2)CCCCCCC3=CC(=C(C=C3)OC4C(C(C(C(O4)CO)O)O)O)C5=CC=CC(=C5)CC(=O)O)OC6C(C(C(C(O6)CO)O)O)O)CC(=O)O
|
|||
| InChI |
1S/C46H54O16/c47-23-35-39(53)41(55)43(57)45(61-35)59-33-15-13-25(19-31(33)29-11-5-9-27(17-29)21-37(49)50)7-3-1-2-4-8-26-14-16-34(60-46-44(58)42(56)40(54)36(24-48)62-46)32(20-26)30-12-6-10-28(18-30)22-38(51)52/h5-6,9-20,35-36,39-48,53-58H,1-4,7-8,21-24H2,(H,49,50)(H,51,52)/t35-,36-,39-,40-,41+,42+,43+,44+,45+,46+/m1/s1
|
|||
| InChIKey |
RYWCQJDEHXJHRI-XJMXIVSISA-N
|
|||
| CAS Number |
CAS 187269-40-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | E-selectin (SELE) | Target Info | Inhibitor | [2], [3], [4] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| TNF signaling pathway | ||||
| African trypanosomiasis | ||||
| Malaria | ||||
| NetPath Pathway | IL5 Signaling Pathway | |||
| IL4 Signaling Pathway | ||||
| TNFalpha Signaling Pathway | ||||
| ID Signaling Pathway | ||||
| Pathway Interaction Database | Thromboxane A2 receptor signaling | |||
| Glucocorticoid receptor regulatory network | ||||
| ATF-2 transcription factor network | ||||
| Reactome | Cell surface interactions at the vascular wall | |||
| WikiPathways | Human Complement System | |||
| TNF alpha Signaling Pathway | ||||
| Cell surface interactions at the vascular wall | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging drugs for asthma. Expert Opin Emerg Drugs. 2008 Dec;13(4):643-53. | |||
| REF 2 | Effects of the pan-selectin antagonist bimosiamose (TBC1269) in experimental human endotoxemia. Shock. 2008 Apr;29(4):475-82. | |||
| REF 3 | The pharmacokinetics of subcutaneously injected Bimosiamose disodium in healthy male volunteers. Biopharm Drug Dispos. 2007 Dec;28(9):475-84. | |||
| REF 4 | Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics... Pulm Pharmacol Ther. 2006;19(4):233-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.